Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,341 total articles
Veradigm (MDRX) trades near its 52-week low but sits on a lean enterprise value, strong free cash flow, and improving technicals. This trade idea lays out a mid-term (45 trading days) long plan with precise entry, stop, and target, backed by valuation and catalysts while balancing realistic execution risks.
Perspective Therapeutics (CATX) has delivered credible Phase 1/2a signals for its [212Pb]VMT-α-NET program and occupies an attractive niche in alpha-emitter radiopharmaceuticals. The stock is trading with meaningful short interest and clinical catalysts ahead; a disciplined long trade targets a move back toward prior highs while protecting against …
ConnectOne (CNOB) is trading near a 52-week high after completing the First of Long Island merger and enjoying support from margin expansion and scale. The trade: take a controlled long position at $29.70 with a $32.00 target and $27.50 stop, horizon roughly 45 trading days. Reward-to-risk looks attractive if loan impairments remain contained; if n…
Dollar Tree is an earnings-and-cycle play. Q4 momentum, a multi-price conversion program and cleaner balance sheet leave the retailer positioned to capture an accelerated 'trade down' as gasoline and living costs bite. Valuation is reasonable versus cash flow and profitability metrics; short interest and heavy short volume create an asymmetric setu…
Lumentum (LITE) has gone from $56.80 (52-week low) to roughly $859 today — a roughly 1,400% move. The company sits at the center of AI data-center optics demand, has a sizable market cap ($~63.9B) and strong profitability metrics, but it now trades at premium multiples and faces execution and cyclicality risks. I am buying a disciplined mid-term lo…
Oruka (ORKA) has surged from its 52-week low and is now trading with significant volume and bullish technicals after market focus on its ORKA-001 IL-23p19 program. We rate ORKA a Strong Buy for nimble, risk-tolerant investors who want exposure to a differentiated psoriasis asset; entry $76.39, stop $62.00, target $120.00 over a 180-trading-day hori…
Fastly's edge computing business is converting AI-driven traffic into real revenue and cash. Recent results, healthy free cash flow and bullish 2026 guidance argue the market can justify a higher multiple. This trade idea lays out an entry at $25.80, a stop at $20.50 and a $34.00 target with timeframes and risk controls for traders and investors.
Frontline's tanker franchise is generating meaningful free cash in a market that looks structurally tighter. With a $1.03 quarterly dividend, a market cap near $8.0B and Q2 2025 operating strength, I initiate a Strong Buy. The trade leans on continued high-interest-rate-driven capital discipline, geopolitics and limited newbuild supply to keep rate…
Chubb is boring by design: disciplined underwriting, strong returns on equity and a history of rising dividends. With a $127.2B market cap, a mid-teens ROE and a P/E near low-teens, Chubb offers a reasonably priced way to collect yield and upside as pricing and capital returns continue. This trade idea sets an entry near current levels and targets …
Medtronic is trading below its short- and mid-term moving averages with a cheap relative yield and solid free cash flow. Near-term sentiment is muted, but underlying fundamentals - $5.41B free cash flow, a $108.8B market cap and a 3.4% yield - provide a margin of safety for a disciplined swing trade. This idea lays out a concrete entry, stop and tw…
Rollins is the clear leader in pest and termite control with durable customer economics and healthy free cash flow. Recent margin compression is real, but the business model - recurring residential contracts, fragmentation that favors consolidation, and a modest balance sheet - supports a constructive trade. I recommend a long entry at current leve…
Netflix offers a defined, mid-term long trade after a pullback into technical support and attractive cash generation. Disney merits a parallel watchlist allocation for investors seeking media exposure, but I refrain from a full trade plan here pending a live quote. The thesis blends valuation, free cash flow, and near-term catalysts — with clear st…
Butler National has quietly shifted from legacy gaming exposure into higher-margin aerospace products and services. Recent quarters show accelerating revenue and outsized operating leverage, Avcon FAA approvals broaden addressable markets, and a $37.0M backlog plus active buybacks improve visibility and shareholder alignment. Technicals support a m…
Capital Clean Energy Carriers (CCEC) offers a compelling long trade: structurally stable LNG/gas shipping cash flows, a recent €250M bond refinancing that eases near-term maturities, and a valuation below book that looks primed for rerating as market visibility and investor appetite for income-returning names improve. Technical momentum and a modes…
Amazon's deepening partnership with Anthropic creates a unique runway: enterprise demand for scalable, safety‑focused generative AI plus Amazon's distribution and infrastructure should drive outsized revenue growth in AWS AI services and higher-margin monetization across retail and advertising. This trade idea lays out an actionable long with entry…
Shell announced a transformational bolt-on in Canada that meaningfully accelerates production growth, yet the company’s refocus across hydrocarbons and renewables will take time to translate into shareholder returns. Market pricing reflects that cadence: a reasonable valuation, a 3.2% yield, and an active buyback program. This trade idea buys the c…
Boeing's mix of accelerating defense demand, a sticky services franchise and improving commercial delivery cadence gives the stock a practical path to $255. Technicals and short-interest flows support a mid-term long trade from $230.82 with a $215 stop and $255 target. Valuation is elevated versus cyclicality, but earnings power and ROE justify a d…
Huntington (HBAN) looks inexpensive relative to its earnings power and carries a chunky dividend yield, but the stock is being held back by lingering execution concerns and a cautious Street. This trade idea buys into the improving net interest income story while limiting downside with a below-support stop and a realistic near-term target.
Nvidia's fundamentals and cash flow justify a higher conviction despite stretched multiples. I upgrade to a constructive long trade: enter on a measured pullback, use a tight stop, and target meaningful upside over the next 45 trading days while monitoring macro and competitor catalysts.
AMD's recent pullback and debate over compute-for-equity deals present an actionable long. The arrangements look dilutive on the surface but buy durable demand, customer lock-in, and lower cash burn for AI scale. The trade: enter $335.485, stop $295.00, target $420.00; horizon biased to a mid-to-long term hold.
Applied Optoelectronics is at the center of a feeding frenzy for high-speed optics driven by AI datacenter builds. Multiple large volume orders (800G and 1.6T), a new Texas manufacturing facility and an ambitious capacity target create a high-upside setup. The stock is volatile and richly valued, so treat this as a high-risk, event-driven long with…
Tesla is primed for a new multi-quarter growth phase driven by AI-led FSD improvements, expanding services and energy products, and robust macro demand for EVs and semiconductors. This trade plan offers a long-term directional buy with a clear entry at $220, stop loss at $185 and a target of $340 over a 180 trading day horizon.
Woori Financial's latest headline miss obscures a fundamentally intact franchise: sticky deposit flows, improving net interest income potential as curves normalize, and an attractive risk/reward if management follows through on capital deployment. We upgrade to Buy and outline an actionable trade with clear entry, stop and target levels.
Regeneron just cleared two big hurdle events: a fast-track FDA approval for Otarmeni and a U.S. government agreement that eases pricing pressure while committing to domestic investment. The setup is actionable: buy near $750.90, target the $821 area and place a protective stop at $700.00 for a mid-term horizon. The trade balances regulatory upside …
Huntington Ingalls (HII) is the principal U.S. builder of large naval surface combatants and carriers and is set to benefit from a proposed $1.5 trillion Pentagon budget and internal productivity gains. The stock is down from its spring highs but still trades at a reasonable multiple given steady free cash flow, modest leverage, and backlog-driven …
